Compliance Rate

Compliance Rate 0%
Compliant submissions 0
Incompliant submissions 0
Total trials 0

My Organizations' Clinical Trials

Showing 248 of 248 entries
View as:

Carbon Nanoparticles and Indocyanine Green for Sentinel Lymph Node Biopsy in Early Stage Cervical Cancer

Phase: N/A Priority: Normal
NCT ID: NCT05167149 Org: User:
Start: 02/28/22 End: 06/30/23 Due: 06/30/24

MRI-guided Lateral Lymph Node Dissection in Rectal Cancer

Phase: N/A Priority: Normal
NCT ID: NCT04850027 Org: User:
Start: 01/01/21 End: 12/31/25 Due: 12/31/26

Paclitaxel Polymeric Micelles and Carboplatin in Combination With Iparomilimab and Tuvonralimab Neoadjuvant Therapy for Triple-negative Breast Cancer

Phase: N/A Priority: Normal
NCT ID: NCT06910072 Org: User:
Start: 04/02/25 End: 10/01/28 Due: 10/01/29

A Multicenter Trial of YSQTG vs. Simulated Agents With Neoadjuvant Chemoradiotherapy or Chemoimmunotherapy for EC

Phase: N/A Priority: Normal
NCT ID: NCT06863831 Org: User:
Start: 08/22/24 End: 10/31/27 Due: 10/31/28

Chidamide in Combination With PD-1 Inhibitor, Bevacizumab, and XELOX for Metastatic Colorectal Cancer

Phase: N/A Priority: Normal
NCT ID: NCT06858969 Org: User:
Start: 04/09/25 End: 01/08/28 Due: 01/08/29

Combine Apatinib Mesylate With PD-1 Antibody SHR-1210 for HCC With High Risk of Recurrence After Radical Resection

Phase: N/A Priority: Normal
NCT ID: NCT03839550 Org: User:
Start: 02/15/19 End: 02/28/23 Due: 02/28/24

Perioperative Study of Iparomlimab and Tuvonralimab in Resectable NSCLC

Phase: N/A Priority: Normal
NCT ID: NCT06897046 Org: User:
Start: 07/10/25 End: 05/25/27 Due: 05/25/28

A Phase II Study of Chemoradiotherapy With Nimotuzumab in Unresectable Esophageal Cancer

Phase: N/A Priority: Normal
NCT ID: NCT04207918 Org: User:
Start: 11/14/19 End: 06/30/23 Due: 06/30/24

Camrelizumab Combined With Pemetrexed and Carboplatin for the Study of EGFR-mutated Lung Squamous NSCLC Treatment

Phase: N/A Priority: Normal
NCT ID: NCT04970043 Org: User:
Start: 07/31/21 End: 07/30/24 Due: 07/30/25

Chidamide Combined With Sintilimab and Bevacizumab for the First-line Treatment of Advanced Liver Cancer

Phase: N/A Priority: Normal
NCT ID: NCT06408623 Org: User:
Start: 05/15/24 End: 05/15/26 Due: 05/15/27

Real-World Study of Chidamide Combined With PD-(L)1 Inhibitors and Anti-Angiogenic Therapy for Advanced MSS-Type Colorectal Cancer

Phase: N/A Priority: Normal
NCT ID: NCT06858956 Org: User:
Start: 03/01/25 End: 05/31/26 Due: 05/31/27

Single-port, Two-port Versus Three-port VATS on Non-small Cell Lung Cancer

Phase: N/A Priority: Normal
NCT ID: NCT02992353 Org: User:
Start: 07/31/16 End: 06/30/19 Due: 06/30/20

Gene Therapy for Neurofibromatosis Type 2 (NF2) with ST002

Phase: N/A Priority: Normal
NCT ID: NCT06834438 Org: User:
Start: 02/15/25 End: 02/01/27 Due: 02/01/28

Study of LTC004 Combine With Toripalimab in Patient With Solid Tumors Resistant to Immunotherapy

Phase: N/A Priority: Normal
NCT ID: NCT06490068 Org: User:
Start: 06/04/24 End: 03/31/26 Due: 03/31/27

Cadonilimab + FOLFOX Versus FOLFOX in the Neoadjuvant Treatment of pMMR/MSS Locally Advanced Colorectal Cancer

Phase: N/A Priority: Normal
NCT ID: NCT06154538 Org: User:
Start: 11/01/23 End: 11/01/28 Due: 11/01/29

Mechanical Bowel Preparation Versus no Bowel Preparation for Esophageal Cancer Surgery

Phase: N/A Priority: Normal
NCT ID: NCT05523960 Org: User:
Start: 09/01/22 End: 04/30/23 Due: 04/30/24

Neoadjuvant Inetetamab Combined With Pertuzumab and Paclitaxel/Carboplatin for Breast Cancer

Phase: N/A Priority: Normal
NCT ID: NCT05749016 Org: User:
Start: 11/01/21 End: 12/01/23 Due: 12/01/24

The Study of Envafolimab Combined With Concurrent Chemoradiotherapy In LS-SCLC

Phase: N/A Priority: Normal
NCT ID: NCT05904015 Org: User:
Start: 08/01/23 End: 06/30/27 Due: 06/30/28

Toripalimab Combined With Chidamide for the Treatment of Relapsed/Refractory Peripheral T-Cell Lymphoma

Phase: N/A Priority: Normal
NCT ID: NCT06492629 Org: User:
Start: 04/03/24 End: 12/31/25 Due: 12/31/26

Neoadjuvant Treatment of Triple-Negative Breast Cancer with Stereotactic Radiotherapy, PD-1 Monoclonal Antibody, and Chemotherapy

Phase: N/A Priority: Normal
NCT ID: NCT06691594 Org: User:
Start: 02/28/25 End: 11/30/30 Due: 11/30/31

PD-L1 Inhibitor + RT ± Ursodeoxycholic Acid in Recurrent/Metastatic HER2-Neg Breast Cancer

Phase: N/A Priority: Normal
NCT ID: NCT06842472 Org: User:
Start: 02/28/25 End: 12/31/29 Due: 12/31/30

Evaluating the Efficacy and Safety of PD-L1 Monoclonal Antibody Combined with VEX Metronomic Chemotherapy and Concurrent or Delayed Radiotherapy in Patients with Advanced HER2-Negative Breast Cancer with Brain Metastasis

Phase: N/A Priority: Normal
NCT ID: NCT06839560 Org: User:
Start: 03/01/25 End: 09/10/28 Due: 09/10/29

Real-world Study of SKB264 Monotherapy or Combination Therapy in Recurrent or Metastatic HER2-negative Breast Cancer

Phase: N/A Priority: Normal
NCT ID: NCT06993506 Org: User:
Start: 08/01/25 End: 10/31/27 Due: 10/31/28